Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) ("Zura†), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and prefunded warrants on February 26, 2026. The offering consisted of 21,200,000 Class A ordinary shar ...